hydroxyurea has been researched along with Colorectal Neoplasms in 17 studies
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil." | 9.10 | Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003) |
| "The aim of the study was to investigate the possibility of dual modulation of UFT with leucovorin and hydroxyurea in a phase II trial of metastatic colorectal cancer." | 9.09 | Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer. ( Aabo, K; Hansen, F; Jakobsen, A; Pfeiffer, P; Sandberg, E, 2001) |
| "Patients with histologically confirmed advanced colorectal cancer were randomized to receive folinic acid (FA; 500 mg/mq in 2-hour intravenous infusion) and 5-fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA), beginning every week for 6 weeks, followed by a 2-week rest period, either without hydroxyurea (HU, arm A) or with HU (35 mg/kg per day) given orally in three administrations (every 8 hours) starting 6 hours after 5FU administration (arm B)." | 9.08 | High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Angiona, S; Belsanti, V; Boni, C; Corgna, E; Di Costanzo, F; Figoli, F; Gasperoni, S; Luppi, G; Malacarne, P; Marzola, M; Passalacqua, R; Sdrobolini, A; Zironi, S, 1998) |
| "Sixty-eight patients with advanced colorectal cancer received every 2 weeks hydroxyurea per os 1." | 6.68 | Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. ( Beerblock, K; Bennamoun, M; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Mal, F; Moreau, S; Soubrane, D; Varette, C; Zylberait, D, 1996) |
| "Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil." | 5.10 | Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003) |
| "The aim of the study was to investigate the possibility of dual modulation of UFT with leucovorin and hydroxyurea in a phase II trial of metastatic colorectal cancer." | 5.09 | Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer. ( Aabo, K; Hansen, F; Jakobsen, A; Pfeiffer, P; Sandberg, E, 2001) |
| "Patients with histologically confirmed advanced colorectal cancer were randomized to receive folinic acid (FA; 500 mg/mq in 2-hour intravenous infusion) and 5-fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA), beginning every week for 6 weeks, followed by a 2-week rest period, either without hydroxyurea (HU, arm A) or with HU (35 mg/kg per day) given orally in three administrations (every 8 hours) starting 6 hours after 5FU administration (arm B)." | 5.08 | High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Angiona, S; Belsanti, V; Boni, C; Corgna, E; Di Costanzo, F; Figoli, F; Gasperoni, S; Luppi, G; Malacarne, P; Marzola, M; Passalacqua, R; Sdrobolini, A; Zironi, S, 1998) |
| "Caracemide was well tolerated with the exception of one death due to sepsis." | 2.69 | A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer. ( Asbury, RF; Goodman, TL; Haller, DG; Lipsitz, S; Smith, TJ; Strnad, CM; Wilding, G; Witte, RS, 1999) |
| "Sixty-eight patients with advanced colorectal cancer received every 2 weeks hydroxyurea per os 1." | 2.68 | Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. ( Beerblock, K; Bennamoun, M; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Mal, F; Moreau, S; Soubrane, D; Varette, C; Zylberait, D, 1996) |
| "Hydroxyurea is an S-phase specific drug." | 2.67 | Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial. ( Blumenreich, MS; Gentile, PS; Hamm, JT; Joseph, UG; Kellihan, MJ; Lalley, KA; Seeger, J; Sherrill, EJ; Sheth, SP; Sullivan, DM, 1993) |
| "The treatment of advanced colorectal cancer has improved in recent years." | 2.38 | Recent advances in the treatment of advanced colorectal cancer. ( Ahlgren, JD; Anderson, N; Kemeny, N; Lokich, JJ, 1993) |
| "Human colorectal cancer cells, HCT116, contain aberrant centrioles composed of disorganized cylindrical microtubules and displaced appendages." | 1.35 | Gamma-tubulin-containing abnormal centrioles are induced by insufficient Plk4 in human HCT116 colorectal cancer cells. ( Arnold, M; Bettencourt-Dias, M; Hoffmann, I; Kuriyama, R; Sandvig, L, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (47.06) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Klotz-Noack, K | 1 |
| Klinger, B | 1 |
| Rivera, M | 1 |
| Bublitz, N | 1 |
| Uhlitz, F | 1 |
| Riemer, P | 1 |
| Lüthen, M | 1 |
| Sell, T | 1 |
| Kasack, K | 1 |
| Gastl, B | 1 |
| Ispasanie, SSS | 1 |
| Simon, T | 1 |
| Janssen, N | 1 |
| Schwab, M | 1 |
| Zuber, J | 1 |
| Horst, D | 1 |
| Blüthgen, N | 1 |
| Schäfer, R | 1 |
| Morkel, M | 1 |
| Sers, C | 1 |
| Kuriyama, R | 1 |
| Bettencourt-Dias, M | 1 |
| Hoffmann, I | 1 |
| Arnold, M | 1 |
| Sandvig, L | 1 |
| Stanziale, SF | 1 |
| Petrowsky, H | 1 |
| Joe, JK | 1 |
| Roberts, GD | 1 |
| Zager, JS | 1 |
| Gusani, NJ | 1 |
| Ben-Porat, L | 1 |
| Gonen, M | 1 |
| Fong, Y | 1 |
| Mabro, M | 1 |
| Louvet, C | 2 |
| André, T | 1 |
| Carola, E | 1 |
| Gilles-Amar, V | 1 |
| Artru, P | 1 |
| Krulik, M | 2 |
| de Gramont, A | 2 |
| Huang, XW | 1 |
| Lieber, A | 1 |
| Tang, ZY | 1 |
| Lawrence, TS | 1 |
| Moyer, MP | 1 |
| Zhang, M | 1 |
| Soria, G | 1 |
| Podhajcer, O | 1 |
| Prives, C | 1 |
| Gottifredi, V | 1 |
| Shimizu, N | 2 |
| Misaka, N | 1 |
| Utani, K | 1 |
| Blumenreich, MS | 1 |
| Kellihan, MJ | 1 |
| Joseph, UG | 1 |
| Lalley, KA | 1 |
| Sherrill, EJ | 1 |
| Sullivan, DM | 1 |
| Hamm, JT | 1 |
| Gentile, PS | 1 |
| Sheth, SP | 1 |
| Seeger, J | 1 |
| Kemeny, N | 1 |
| Lokich, JJ | 1 |
| Anderson, N | 1 |
| Ahlgren, JD | 1 |
| Matei, D | 1 |
| Hagag, N | 1 |
| Madajewicz, S | 1 |
| Chowhan, N | 1 |
| Hentschel, P | 1 |
| Avvento, L | 1 |
| Burns, P | 1 |
| Fiore, J | 1 |
| Lipera, W | 1 |
| Zarrabi, H | 1 |
| Bennamoun, M | 1 |
| Varette, C | 1 |
| Demuynck, B | 1 |
| Beerblock, K | 1 |
| Moreau, S | 1 |
| Soubrane, D | 1 |
| Mal, F | 1 |
| Grangé, JD | 1 |
| Zylberait, D | 1 |
| Di Costanzo, F | 2 |
| Gasperoni, S | 1 |
| Malacarne, P | 2 |
| Belsanti, V | 1 |
| Luppi, G | 1 |
| Marzola, M | 2 |
| Corgna, E | 1 |
| Sdrobolini, A | 1 |
| Passalacqua, R | 2 |
| Figoli, F | 2 |
| Algeri, R | 2 |
| Zironi, S | 2 |
| Angiona, S | 1 |
| Boni, C | 1 |
| O'Byrne, KJ | 1 |
| Philip, PA | 1 |
| Propper, DJ | 1 |
| Braybrooke, JP | 1 |
| Saunders, MP | 1 |
| Bates, NP | 1 |
| Taylor, MA | 1 |
| Madigan, D | 1 |
| Ganesan, TS | 1 |
| Talbot, DC | 1 |
| Harris, AL | 1 |
| Witte, RS | 1 |
| Lipsitz, S | 1 |
| Goodman, TL | 1 |
| Asbury, RF | 1 |
| Wilding, G | 1 |
| Strnad, CM | 1 |
| Smith, TJ | 1 |
| Haller, DG | 1 |
| Shimura, T | 1 |
| Tanaka, T | 1 |
| Jakobsen, A | 1 |
| Pfeiffer, P | 1 |
| Hansen, F | 1 |
| Sandberg, E | 1 |
| Aabo, K | 1 |
| Cornia, E | 1 |
| Bacchi, M | 1 |
| Bartolucci, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.[NCT04392479] | Phase 3 | 202 participants (Anticipated) | Interventional | 2020-09-02 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydroxyurea and Colorectal Neoplasms
| Article | Year |
|---|---|
Recent advances in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Drug Administra | 1993 |
9 trials available for hydroxyurea and Colorectal Neoplasms
| Article | Year |
|---|---|
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2003 |
Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Adenoid Cystic; Colorectal Neoplasms; Drug Administration | 1993 |
Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; H | 1995 |
Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1996 |
High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1998 |
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Colorectal Neoplasms; Female; Harringtonines; Ho | 1999 |
Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2001 |
Preliminary report of high dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1991 |
7 other studies available for hydroxyurea and Colorectal Neoplasms
| Article | Year |
|---|---|
SFPQ Depletion Is Synthetically Lethal with BRAF
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Colorectal Neopla | 2020 |
Gamma-tubulin-containing abnormal centrioles are induced by insufficient Plk4 in human HCT116 colorectal cancer cells.
Topics: Centrioles; Colorectal Neoplasms; HCT116 Cells; Humans; Hydroxyurea; Microtubules; Nocodazole; Prote | 2009 |
Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase.
Topics: Animals; Antigens, Differentiation; Cell Cycle Proteins; Colorectal Neoplasms; Enzyme Inhibitors; Ge | 2002 |
Gene expression in intrahepatic tumors through DNA recombination by a replication-activated adenovirus vector.
Topics: Adenoviridae; Animals; beta-Galactosidase; Cell Line, Tumor; Colorectal Neoplasms; DNA; DNA, Viral; | 2004 |
P21Cip1/WAF1 downregulation is required for efficient PCNA ubiquitination after UV irradiation.
Topics: Antineoplastic Agents; Aphidicolin; Cell Cycle; Cell Proliferation; Cells, Cultured; Colorectal Neop | 2006 |
Nonselective DNA damage induced by a replication inhibitor results in the selective elimination of extrachromosomal double minutes from human cancer cells.
Topics: Cell Division; Chromatin; Chromosome Aberrations; Colorectal Neoplasms; DNA Damage; DNA Repair; DNA | 2007 |
Selective elimination of acentric double minutes from cancer cells through the extrusion of micronuclei.
Topics: Cell Nucleus; Chromatin; Coiled Bodies; Colorectal Neoplasms; Extracellular Matrix; Gene Amplificati | 2000 |